Work

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.9038

Authors: Gregory James Gerstner, Suresh S. Ramalingam, Aaron E. Lisberg, Charles Michael Farber, Neil Morganstein, Rachel E. Sanborn, Balazs Halmos, Alexander I. Spira, Ranjan Pathak, Chao Hui Huang, Surya Vangala, Megan Parsi, Cristiane Metran, Andres A. Gutierrez, Jonathan W. Goldman

Institutions: Illinois CancerCare, Winship Cancer Institute, University of California, Los Angeles, Morristown Medical Center, Overlook Medical Center, Providence Portland Medical Center, Albert Einstein College of Medicine, Montefiore Medical Center, Yale University, University of Kansas Medical Center, Advaxis (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281720062

Cites:

Cited by: 15

Related to: 10